24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data have been compared with the previous report, and short interest in most…
Here are five top health care stocks that recently saw their 50-day moving average cross below the 200-day average, a death cross.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 31 short interest data have been compared with the previous report, and short interest in most…
There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options for devices,…
The January 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The December 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Teva Pharmaceutical shares made a handy gain on Thursday after it was announced that the firm has settled with Amgen for its treatment of secondary hyperparathyroidism in adult patients with chronic kidney…
The December 14 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The November 30 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The November 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The October 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The October 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The September 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The top analyst upgrades, downgrades and initiations seen on Monday included Amgen, Chipotle Mexican Grill, Lam Research, Netgear, Teva Pharmaceutical and Western Digital.
Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
